81 related articles for article (PubMed ID: 30470491)
1. Discovery of novel pyruvate dehydrogenase kinases inhibitors by screening of an in-house small molecule library for anti-lung cancer therapeutics.
Guo F; Zhao S; Li X
Bioorg Med Chem Lett; 2019 Jan; 29(2):291-296. PubMed ID: 30470491
[TBL] [Abstract][Full Text] [Related]
2. Targeting the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis to discover potent PDK inhibitors through structure-based virtual screening and pharmacological evaluation.
Gan L; Yang Y; Liang Z; Zhang M; He Y; Zhang SL
Eur J Med Chem; 2024 Jan; 264():116008. PubMed ID: 38056298
[TBL] [Abstract][Full Text] [Related]
3. Identification of a dual TAOK1 and MAP4K5 inhibitor using a structure-based virtual screening approach.
Chao MW; Lin TE; HuangFu WC; Chang CD; Tu HJ; Chen LC; Yen SC; Sung TY; Huang WJ; Yang CR; Pan SL; Hsu KC
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):98-108. PubMed ID: 33167727
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
Alsfouk A
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
[TBL] [Abstract][Full Text] [Related]
5. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
[TBL] [Abstract][Full Text] [Related]
6. Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically by binding to its pyruvate regulatory site.
Masini T; Birkaya B; van Dijk S; Mondal M; Hekelaar J; Jäger M; Terwisscha van Scheltinga AC; Patel MS; Hirsch AK; Moman E
J Enzyme Inhib Med Chem; 2016; 31(sup4):170-175. PubMed ID: 27435185
[TBL] [Abstract][Full Text] [Related]
7. Discovery of carbazole derivatives as novel allosteric MEK inhibitors by pharmacophore modeling and virtual screening.
Xi D; Niu Y; Li H; Noha SM; Temml V; Schuster D; Wang C; Xu F; Xu P
Eur J Med Chem; 2019 Sep; 178():802-817. PubMed ID: 31252285
[TBL] [Abstract][Full Text] [Related]
8. Structure-based investigation of pyruvate dehydrogenase kinase-3 inhibitory potential of thymoquinone, targeting lung cancer therapy.
Alotaibi BS; Hakami MA; Anwar S; Mawkili W; Albaqami A; Hassan MI
Int J Biol Macromol; 2024 Apr; 265(Pt 2):131064. PubMed ID: 38518935
[TBL] [Abstract][Full Text] [Related]
9. Selective Phosphorylation Inhibitor of Delta Protein Kinase C-Pyruvate Dehydrogenase Kinase Protein-Protein Interactions: Application for Myocardial Injury in Vivo.
Qvit N; Disatnik MH; Sho E; Mochly-Rosen D
J Am Chem Soc; 2016 Jun; 138(24):7626-35. PubMed ID: 27218445
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 3,4-Dihydrobenzo[
Li Y; Zhang L; Yang R; Qiao Z; Wu M; Huang C; Tian C; Luo X; Yang W; Zhang Y; Li L; Yang S
J Med Chem; 2022 Feb; 65(3):1786-1807. PubMed ID: 34985886
[TBL] [Abstract][Full Text] [Related]
11. Discovery of
Liu L; Zhao L; Yang L; Chai M; Liu Z; Ma N; Wang Y; Wu Q; Guo J; Zhou F; Huang W; Ren X; Wang J; Ding M; Wang Z; Ding K
J Med Chem; 2024 May; 67(10):8043-8059. PubMed ID: 38730324
[TBL] [Abstract][Full Text] [Related]
12. Scaffold-focused virtual screening: prospective application to the discovery of TTK inhibitors.
Langdon SR; Westwood IM; van Montfort RL; Brown N; Blagg J
J Chem Inf Model; 2013 May; 53(5):1100-12. PubMed ID: 23672464
[TBL] [Abstract][Full Text] [Related]
13. New inhibitor of 3-phosphoinositide dependent protein kinase-1 identified from virtual screening.
Yang W; AbdulHameed MD; Hamza A; Zhan CG
Bioorg Med Chem Lett; 2012 Feb; 22(4):1629-32. PubMed ID: 22266037
[TBL] [Abstract][Full Text] [Related]
14. Target-specific support vector machine scoring in structure-based virtual screening: computational validation, in vitro testing in kinases, and effects on lung cancer cell proliferation.
Li L; Khanna M; Jo I; Wang F; Ashpole NM; Hudmon A; Meroueh SO
J Chem Inf Model; 2011 Apr; 51(4):755-9. PubMed ID: 21438548
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel histone H2A mono-ubiquitination-inhibiting cell-active small molecule.
Ni S; Takada Y; Ando T; Yu S; Yamashita Y; Takahashi Y; Sawada M; Oba M; Itoh Y; Suzuki T
Bioorg Med Chem Lett; 2024 Jun; 105():129759. PubMed ID: 38636717
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods.
Kroon E; Schulze JO; Süß E; Camacho CJ; Biondi RM; Dömling A
Angew Chem Int Ed Engl; 2015 Nov; 54(47):13933-6. PubMed ID: 26385475
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in pyruvate dehydrogenase kinase inhibitors: Structures, inhibitory mechanisms and biological activities.
Li Y; Xie Z; Lei X; Yang X; Huang S; Yuan W; Deng X; Wang Z; Tang G
Bioorg Chem; 2024 Mar; 144():107160. PubMed ID: 38301426
[TBL] [Abstract][Full Text] [Related]
18. PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor.
Tamir TY; Drewry DH; Wells C; Major MB; Axtman AD
Sci Rep; 2020 Sep; 10(1):15826. PubMed ID: 32985588
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer analysis reveals PDK family as potential indicators related to prognosis and immune infiltration.
Tao S; Tao K; Cai X
Sci Rep; 2024 Mar; 14(1):5665. PubMed ID: 38453992
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Target-Specific Screening Leads to Small-Molecule CaMKII Inhibitors.
Xu D; Li L; Zhou D; Liu D; Hudmon A; Meroueh SO
ChemMedChem; 2017 May; 12(9):660-677. PubMed ID: 28371191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
